Evercore Begins Coverage on TRex Bio (NASDAQ:TRXB)

Evercore assumed coverage on shares of TRex Bio (NASDAQ:TRXB) in a research report issued to clients and investors on Tuesday, Zacks reports. The firm set a “strong-buy” rating on the stock.

Other equities research analysts have also recently issued reports about the company. Stifel Nicolaus assumed coverage on TRex Bio in a research report on Tuesday. They set a “buy” rating and a $39.00 target price on the stock. Wedbush initiated coverage on TRex Bio in a research note on Monday. They issued an “outperform” rating and a $30.00 price target for the company. Cantor Fitzgerald began coverage on TRex Bio in a report on Tuesday. They issued an “overweight” rating for the company. Finally, JPMorgan Chase & Co. began coverage on TRex Bio in a research report on Tuesday. They set an “overweight” rating and a $20.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $29.67.

TRex Bio Price Performance

TRXB opened at $13.55 on Tuesday. TRex Bio has a fifty-two week low of $12.50 and a fifty-two week high of $16.56.

Insider Buying and Selling

In related news, major shareholder Alexandria Venture Investments purchased 178,571 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The stock was bought at an average price of $14.00 per share, with a total value of $2,499,994.00. Following the acquisition, the insider owned 1,346,501 shares in the company, valued at $18,851,014. The trade was a 15.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

About TRex Bio

We are a clinical-stage biopharmaceutical company focused on tissue Treg biology for the discovery and development of immunoregulatory medicines designed to restore immune balance and promote tissue repair to address unmet needs of patients with autoimmune and inflammatory diseases. TRexBio was built on a pivotal scientific insight: that regulatory T cells (“Tregs”) in human tissue are not merely passive suppressors of inflammation, but active orchestrators of tissue immune homeostasis and repair.